Drug Developers’ Statements Not Available as Evidence of Obviousness

The U.S. Court of Appeals for the Federal Circuit (CAFC) in Eli Lilly & Co. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2010) affirmed a permanent...

Daiichi Sankyo v. Matrix, Mylan

The U.S. Court of Appeals for the Federal Circuit (CAFC) in Eli Lilly & Co. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2010) affirmed a permanent...

USPTO Obviousness Examination Guidelines Updated

On September 1, the United States Patent and Trademark Office (USPTO) published 2010 KSR Guidelines Update, an update on the guidelines for examination of patent...

Law Could Provide Protection for Fashion Designs

On August 5, 2010, Democratic Senator Charles Schumer and several notable cosponsors, including four Republicans, introduced a bill to extend intellectual property protection to fashion...

United States Patent and Trademark Office Issues Interim Guidance on Machine or Transformation Test

The U.S. Court of Appeals for the Federal Circuit (CAFC) in Eli Lilly & Co. v. Teva Pharmaceuticals USA, Inc.(Fed. Cir. 2010) affirmed a permanent...

Additional Disclosure of Use Revokes Patent Validity

In Sun Pharmaceutical Industries v. Eli Lilly and Co., the Court of Appeals for the Federal Circuit (CAFC) ruled U.S. Patent No. 5,464,826 (US ‘826) invalid...
1 8 9 10

Categories

Archive

MWZB Newsletter Signup

Subscribe
Confidential/Privileged Information MWZB is pleased that you would like to contact the firm. However, you should be aware that any information, documents and the like submitted in connection with this email message or otherwise via the firm’s website will not be treated as a privileged or confidential attorney/client communication unless and until the relationship is governed by an engagement letter. You are not a client of MWZB in the absence of such an engagement letter. If you understand and accept these terms and wish to proceed, please enter your email address below.

Newsletter Signup